Research programme: cancer therapeutics - Istesso
Latest Information Update: 04 Nov 2017
At a glance
- Originator University of Manchester; University of Salford
- Developer Istesso
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 23 Aug 2007 Preclinical development is ongoing